Cargando…
Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature
Background: High-titer convalescent plasma given early for COVID-19 may decrease progression into a severe infection. Here, we reported a study of serial antibody measurements in patients who received CP at our center and performed a systematic review of randomized trials on CP. Methods: Our center...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503397/ https://www.ncbi.nlm.nih.gov/pubmed/36145390 http://dx.doi.org/10.3390/pathogens11090958 |
_version_ | 1784795952937172992 |
---|---|
author | Whang, Sonia N. Shah, Vivek D. Pu, Lu Sheth, Parthiv Lucas, Gina N. Lee, Joanne Lee, Michael Lacy, Curtis Duerksen-Hughes, Penelope J. Filippov, Valeri Lee, David J. H. Veltman, Jennifer Maken, Kanwaljeet Reeves, Mark E. Stevens, Wesley Tait Herrmann, Paul Cao, Huynh Lau, Eric |
author_facet | Whang, Sonia N. Shah, Vivek D. Pu, Lu Sheth, Parthiv Lucas, Gina N. Lee, Joanne Lee, Michael Lacy, Curtis Duerksen-Hughes, Penelope J. Filippov, Valeri Lee, David J. H. Veltman, Jennifer Maken, Kanwaljeet Reeves, Mark E. Stevens, Wesley Tait Herrmann, Paul Cao, Huynh Lau, Eric |
author_sort | Whang, Sonia N. |
collection | PubMed |
description | Background: High-titer convalescent plasma given early for COVID-19 may decrease progression into a severe infection. Here, we reported a study of serial antibody measurements in patients who received CP at our center and performed a systematic review of randomized trials on CP. Methods: Our center participated in the Mayo Clinic Expanded Access Program for COVID-19 Convalescent Plasma. Patients diagnosed with COVID-19 by nasopharyngeal polymerase chain reaction at our center between April and August 2020 were included in the study if staffing was available for specimen collection. Through a colloidal gold immunochromatography assay, these patients’ IgM and IgG antibody responses were measured at baseline (Day 0) and after transfusion (Day 1, 2, etc.). Donor CP antibody levels were measured as well. Results: 110 serum specimens were obtained from 21 COVID-19 patients, 16 of whom received CP. The median time from developing symptoms to receiving CP was 11 days (range 4–21). In 9 of 14 (64%) cases where both recipient and donor CP antibody levels were tested, donor COVID-19 IgG was lower than that of the recipient. Higher donor antibody levels compared with the recipient (R = 0.71, p < 0.01) and low patient IgG before CP transfusion (p = 0.0108) correlated with increasing patient IgG levels from baseline to Day 1. Among all patients, an increased COVID-19 IgG in the short-term and longitudinally was positively correlated with improved clinical outcomes (ρ = 0.69, p = 0.003 and ρ = 0.58, p < 0.006, respectively). Conclusions: In a real-world setting where donor CP was not screened for the presence of antibodies, CP in donors might have less COVID-19 IgG than in recipients. An increase in patient antibody levels in the short term and longitudinally was associated with improved clinical outcomes. |
format | Online Article Text |
id | pubmed-9503397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95033972022-09-24 Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature Whang, Sonia N. Shah, Vivek D. Pu, Lu Sheth, Parthiv Lucas, Gina N. Lee, Joanne Lee, Michael Lacy, Curtis Duerksen-Hughes, Penelope J. Filippov, Valeri Lee, David J. H. Veltman, Jennifer Maken, Kanwaljeet Reeves, Mark E. Stevens, Wesley Tait Herrmann, Paul Cao, Huynh Lau, Eric Pathogens Article Background: High-titer convalescent plasma given early for COVID-19 may decrease progression into a severe infection. Here, we reported a study of serial antibody measurements in patients who received CP at our center and performed a systematic review of randomized trials on CP. Methods: Our center participated in the Mayo Clinic Expanded Access Program for COVID-19 Convalescent Plasma. Patients diagnosed with COVID-19 by nasopharyngeal polymerase chain reaction at our center between April and August 2020 were included in the study if staffing was available for specimen collection. Through a colloidal gold immunochromatography assay, these patients’ IgM and IgG antibody responses were measured at baseline (Day 0) and after transfusion (Day 1, 2, etc.). Donor CP antibody levels were measured as well. Results: 110 serum specimens were obtained from 21 COVID-19 patients, 16 of whom received CP. The median time from developing symptoms to receiving CP was 11 days (range 4–21). In 9 of 14 (64%) cases where both recipient and donor CP antibody levels were tested, donor COVID-19 IgG was lower than that of the recipient. Higher donor antibody levels compared with the recipient (R = 0.71, p < 0.01) and low patient IgG before CP transfusion (p = 0.0108) correlated with increasing patient IgG levels from baseline to Day 1. Among all patients, an increased COVID-19 IgG in the short-term and longitudinally was positively correlated with improved clinical outcomes (ρ = 0.69, p = 0.003 and ρ = 0.58, p < 0.006, respectively). Conclusions: In a real-world setting where donor CP was not screened for the presence of antibodies, CP in donors might have less COVID-19 IgG than in recipients. An increase in patient antibody levels in the short term and longitudinally was associated with improved clinical outcomes. MDPI 2022-08-23 /pmc/articles/PMC9503397/ /pubmed/36145390 http://dx.doi.org/10.3390/pathogens11090958 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Whang, Sonia N. Shah, Vivek D. Pu, Lu Sheth, Parthiv Lucas, Gina N. Lee, Joanne Lee, Michael Lacy, Curtis Duerksen-Hughes, Penelope J. Filippov, Valeri Lee, David J. H. Veltman, Jennifer Maken, Kanwaljeet Reeves, Mark E. Stevens, Wesley Tait Herrmann, Paul Cao, Huynh Lau, Eric Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature |
title | Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature |
title_full | Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature |
title_fullStr | Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature |
title_full_unstemmed | Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature |
title_short | Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature |
title_sort | convalescent plasma for covid-19: a single center prospective experience with serial antibody measurements and review of the literature |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503397/ https://www.ncbi.nlm.nih.gov/pubmed/36145390 http://dx.doi.org/10.3390/pathogens11090958 |
work_keys_str_mv | AT whangsonian convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT shahvivekd convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT pulu convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT shethparthiv convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT lucasginan convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT leejoanne convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT leemichael convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT lacycurtis convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT duerksenhughespenelopej convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT filippovvaleri convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT leedavidjh convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT veltmanjennifer convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT makenkanwaljeet convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT reevesmarke convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT stevenswesleytait convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT herrmannpaul convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT caohuynh convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature AT laueric convalescentplasmaforcovid19asinglecenterprospectiveexperiencewithserialantibodymeasurementsandreviewoftheliterature |